Archive | March, 2014

Women CEOs Lead the Day at the RESI Innovation Challenge

27 Mar

By Maximilian Klietmann, VP of Marketing, LSN

Max Smile 2

RESI ended on Monday evening with over 400 attendees and over 660 partnering meetings. Additionally, 33 of the 150 biotech and medtech companies attending RESI were selected for the RESI Innovation Challenge, and competed for “RESI Cash” invested by conference attendees. Well, the winners are in:

  • The winners are global in nature, hailing from the US and Europe.
  • There was a tie for third place.
  • Women led the charge! Three of the four winning companies have women CEOs.

Scroll down to see the winning companies below (click the logos to visit company websites):

FIRST PLACE:

EMPIRIKO

Empiriko, based in Newton, MA, is addressing several of the challenges faced by scientists, clinicians and decision-makers responsible for taking drugs from concept to commercialization. The company’s Biomimiks™ solutions can help in predicting patient/drug interaction and can be used to optimize drug designs, and improve patient outcomes.

Pam Randhawa, Founder and CEO


SECOND PLACE:

BIOARRAY

BIOARRAY, based in Farmington, CT, is developing proprietary predictive diagnostic tests, based on cancer genes (markers), to choose the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used.

Marcia Fournier, CEO


THIRD PLACE (TIE):

STC logo

STC Biologics is a biotechnology company located in Cambridge MA focusing on development of biologic drugs. The company’s portfolio of drugs includes a MAb biosimilar for Oncology as well as a re-appropriated biologic drug for the treatment of Alzheimer’s.

Magdalena Leszczyniecka, President and CEO


THIRD PLACE (TIE):

Multineurons_logotype_300dpi

Multineurons, based in Switzerland, is developing medical devices for non-invasive and wireless brain-computer interface and brain diagnosis/therapy. The company’s products are based on a unique technology that evolved from more than a decade of R&D. 

Tasos Smeros, Founder & CEO

Hot Life Science Investor Mandate 1: Family Office Seeking Therapeutics, Biologics and Small Molecules

27 Mar

A private investment company established by a single high net worth individual is looking to make direct investments in the therapeutics space.  Based in New York City the firm manages an evergreen structure allowing it to have a very large range for investment size, capital structure, and holding period. The firm has no set number of allocations that it plans to make over the next 6-9 months and will evaluate all relevant opportunities on a case by case basis.

The firm is currently looking for US based companies in the therapeutics space and is open to considering both Biologics and Small Molecules. Companies with assets in phase II or later are of high interest, and companies in phase I that have some human efficacy data are also open to consideration. The firm is not interested in therapeutics areas with subjective endpoints such as pain and mental disorders.

The firm is looking for both private and micro-cap publicly held companies and evaluates management on a case-by-case basis. Taking a board seat is not a requirement for the firm and their involvement in the management of the firm varies based on the needs of the company. The firm is interested in both leading as well as co-investing in investment rounds.

Hot Life Science Investor Mandate 2: Multi-family Office Seeking Medical Devices and Therapeutic Drug Development

27 Mar

A multi-family office based in the Greater Cincinnati area is looking to make direct investments in a variety of sectors including healthcare & life sciences.  Investments from this firm in early-stage companies are typically in the form of equity, whereas debt investments in later-stage companies may be considered.  The firm’s allocations are highly variable but are typically at least $3 million.  The firm primarily invests in US-based companies but Canada-based companies may also be considered.

Within the life science sector the firm has diverse interests, with a primary focus on medical devices and medical service providers (including biotech R&D services and healthcare IT companies).  Investments in therapeutic drug development may also be considered.  The firm is a generalist investor, and is open to investing in both preclinical and clinical-stage companies and considers opportunities on a case-by-case basis.  While the firm will consider investments in almost any indication, the firm prefers to invest in large markets and does not consider investment opportunities in rare diseases.

The Firm seeks to invest in solid management teams that have developed a product based on proprietary, patented technology.  While the firm does make investments into pre-revenue companies, they require that the company have a clearly defined path to revenue.

Hot Life Science Investor Mandate 3: Venture Capital Seeking Medical Technology, Therapeutics and Companion Diagnostics

27 Mar

A life-sciences focused venture capital incubator accelerator based in San Francisco, California is looking to provide capital in the form of equity and convertible notes to seed and venture stage companies in the life science space. The firm can provide capital in the range of a few hundred thousand to $2million or more by leveraging its groups of angel syndicates. The firm invests in companies across the United States, Europe and Australia with a preference for California based companies. The firm looks to be involved in 3 new companies per year.

The firm is currently looking for companies in areas of Medical Technology/Devices, Therapeutics and Companion Diagnostics. In the Medical Device space the firm is open in terms of sector and indication and will consider firms that are in the development phase as well as those that have entered clinical trials. In the therapeutics space the firm is generally open as well however the firm is highly interested in areas of cell and gene therapy and oncology. For therapeutics the firm tends to get involved at the preclinical stage or during phase I of clinical trials.

The firm is looking for confident and experienced management teams. Given the early stage investment style that the firm has, they often work with management teams that are incomplete and have primarily academic backgrounds. Part of the value that the firm looks to add is helping firms fill in the gaps in their current management.

Content is King – The RESI Mantra

20 Mar

By Maximilian Klietmann, VP of Marketing, LSN

Max Smile 2The Redefining Early Stage Investments (RESI) Conference is poised to launch on Monday. Getting this 400 person event together was no small feat: The RESI team relied heavily on a strict strategy on delivering quality content that was current, relevant, and compelling. The main tactic was to focus on early stage investment and really understand how that impacts emerging life science startups. When LSN embarked on the RESI Conference, there was a single mantra that drove the entire event organization process: Content is king. So many conferences recycle dry outdated content, and it’s the same old speakers with the same old content. This is precisely what LSN sought to change.

A brief glance at the RESI agenda shows that we succeeded: There are 16 panels covering topics such as family offices investing directly, non-profits adopting for-profit models, CROs investing into startups, the latest big pharma in-licensing activities, and other emerging trends in early stage life science investing. On top of that, there are workshops covering how to conduct a fundraising campaign, the legal landscape, and valuation.

So how exactly was LSN able to compile all of this content? Quite simply, it comes down to the fact that LSN’s primary business is working together with early stage companies raising capital, and profiling the investor landscape. LSN tracks over 5,000 active biotech and medtech investors around the world, and the LSN research team maintains an ongoing dialogue with them on a 90-day rolling basis. This gives LSN unequaled insight into the latest investor trends, but also fosters a relationship that allows for a higher ratio of active investors than any other major life science conference in the world.

The insights that LSN research compiles allow the RESI conference content to stay abreast of the industry. The RESI event’s content is designed to give perspectives on what’s happening now, who’s active, what’s hot, and what the future looks like on a tactical level. Moreover, because of LSN’s relationship with the senior staff at each of these investor entities, the content is delivered by the very people who are redefining early stage investments in the life science arena.

If you’re already a part of the RESI tribe, we look forward to seeing you all on March 24th in Boston. If you’re not part of the tribe yet, it’s not too late, but time is running short. Come see what everyone’s talking about!

A Closer Look at Who’s Going to RESI

20 Mar

By Tom Crosby, RESI Conference Manager, LSN

Tom 2Next Monday, March 24th will mark the date for Life Science Nation’s second Redefining Early Stage Investments Conference in Boston’s State Room. Nearly 400 active early stage life science investors, biotech and medtech innovators, and senior executives from all segments of the industry will converge 33 floors above the city for a full day.

LSN’s motivation to create the RESI conference is based on a simple concept: while the world of early stage life science investments has fundamentally changed, many fundraising executives are still operating under the assumption that the old process for raising capital is still applicable. In light of this, LSN conceived the concept of a forum of entrepreneurs and active early stage investors not only to discuss the new marketplace, but also to initiate dialogues that would eventually lead to allocations. This is accomplished by a combination of top-tier investor panels, workshops, and a full-day partnering pavilion.

Ultimately, the key differentiator for RESI is that it is a targeted event seeking to connecting early stage technologies with investors – therapeutics, diagnostics, medtech, healthcare IT, and investors from 10 categories are all represented. It’s not indication specific, it’s not just for biotech, and it’s not just for medtech; it is the only conference that focuses on bridging the funding void that traditional investors have left.

So, what does RESI look like this time around? Let’s take a look at the numbers:

·         Total Attendees: 390 attendees from 377 organizations

·         Countries Represented:  12 different countries, and representation from across the US

TOM

Moreover, the ratio of investors to companies seeking capital is close to 1:1, which outperforms any other meeting on this scale of which LSN is aware. As a company – and as an conference – LSN and the RESI Conference continue to fill gaps in the market, create disruptive events, and ultimately, be an advocate for early stage companies seeking to move science forward.

Life Science Investors Step Into The Spotlight

20 Mar

By Dennis Ford, Founder & CEO, LSN

Dennis book

I created the RESI conference as a result of canvassing all the “investor” conferences worldwide and finding few actual investors participating. The Redefining Early Stage Investments Conference is a full day conference targeted at moving early stage biotech and medtech companies forward by fostering dialogue between innovators and active investors from around the world. With more than 400 attendees and over 500 partnering meetings already scheduled for next Monday, March 24th, the RESI conference is poised to be “the” investor partnering conference this year. Moreover, there is nearly a 1:1 ratio of early stage fundraising companies and active investors at RESI, suggesting that it will be unparalleled in terms of fundraising opportunity.

RESI has partnered with Meeting Mojo, an emerging partnering portal based in the UK. Together RESI and Meeting Mojo have created a customized solution based on providing in depth, meta tagged, profiles that can be searched by conference attendees for a specific fit for their firm and product. In addition, by leveraging LSN’s Investor Platform we were able to provide added depth by importing current investment mandate data directly into the investor profiles. This has provided the foundation for a great partnering experience based on current investor mandates matching up with emerging biotech and medtech startups that fit the investment criteria.

One of the most compelling facts is that more than half the meetings already scheduled are between biotech/medtech companies and investors. This equates to 263 discussions taking place in under 10 hours. LSN’s analysis shows interesting trends in the charts provided. For example, the third biggest category of meetings is among investors meeting with other investors. This makes sense, as a good amount of investors are looking for co-investors and partners for their portfolio companies. Another emerging trend is that service providers are eager to meet with investors. One explanation for this is that service providers are now funding promising startups and seeking to partner with investors as part of the new paradigm thus becoming a new deal sourcing channel.

The Redefining Early Stage Investment conference continues to evolve as partnering takes on a life of its own. There are 700 potential meetings at RESI, and there are bound to be some fascinating results.

RESI MEETINGS PERCENTAGE
Investor & Biotech/Medtech 54%
Biotech/Medtech & Service Provider/Consultant 20%
Investor & Investor 7%
Investor & Service Provider/Consultant 7%
Miscellaneous 6%
Biotech/Medtech & Government Organization 2%
Service Provider/Consultant & Service Provider/Consultant 2%
Investor & Government Organizations 1%
Biotech/Medtech & Biotech/Medtech 1%
Government Organization & Service Provider/Consultant 1%

Alej